SCHEMBL10140922

SCHEMBL10140922

NC(=O)C(N)(c1cccc(C(F)(F)F)c1)C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.50
HTR3E A5X5Y0 1/20 0.46
HTR3B O95264 1/20 0.46
HTR3A P46098 1/20 0.46
HTR3D Q70Z44 1/20 0.46
HTR3C Q8WXA8 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
KIF11 P52732 2/20 0.45
ALDH1A1 P00352 3/20 0.45
EPHX1 P07099 3/20 0.44
MAPT P10636 2/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
P2RX1 P51575 1/20 0.44
KCNN4 O15554 1/20 0.43
SRD5A2 P31213 1/20 0.42
MEN1 O00255 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377397 0.86 CES2 (0.50) CES2HTR3EHTR3BHTR3AHTR3D
SCHEMBL16892940 0.79 CES2 (0.55) CES2HTR3EHTR3BHTR3AHTR3D
SCHEMBL169141 0.79 HTR3E (0.50) CES2HTR3EHTR3BHTR3AHTR3D
SCHEMBL10140894 0.79 HTR3E (0.50) CES2HTR3EHTR3BHTR3AHTR3D
SCHEMBL10140895 0.79 HTR3E (0.50) CES2HTR3EHTR3BHTR3AHTR3D
Hydrochloric Acid SCHEMBL27844889 0.77 HTR3E (0.49) CES2HTR3EHTR3BHTR3AHTR3D
Hydrochloric Acid SCHEMBL717776 0.77 HTR3E (0.49) CES2HTR3EHTR3BHTR3AHTR3D
Hydrochloric Acid SCHEMBL717668 0.77 HTR3E (0.49) CES2HTR3EHTR3BHTR3AHTR3D
SCHEMBL22655989 0.76 MAPT (0.60) CES2HTR3EHTR3BHTR3AHTR3D
SCHEMBL31691810 0.76 MAPT (0.60) CES2HTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-01 US disclosed
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY AVPR2, AVPR1B, AVPR1A CES2 3566/4885HTR3E 313/4885HTR3B 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.